[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337119-105":59,"doc-detail-337119-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-evidence-of-trastuzumab-deruxtecan-t-dxd-efficacy-in-her2-expressing-gynecological-malignancies","Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies","","HER2 overexpression represents a promising therapeutic target in gynecological malignancies. Trastuzumab-Deruxtecan (T-DXd) has demonstrated meaningful efficacy in HER2-overexpressing carcinomas, particularly ovarian, endometrial, and cervical cancers. This study evaluates real-world T-DXd activity in metastatic endometrial, ovarian, and cervical cancers treated at a clinical therapeutics department, focusing on treatment outcomes in routine clinical practice.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-evidence-of-trastuzumab-deruxtecan-t-dxd-efficacy-in-her2-expressing-gynecological-malignancies/337119/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-evidence-of-trastuzumab-deruxtecan-t-dxd-efficacy-in-her2-expressing-gynecological-malignancies/337119.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which patients were included in the real-world T-DXd efficacy analysis?","Question",{"text":112,"@type":113},"Patients with metastatic endometrial, ovarian, and cervical malignancies with HER2 expression 2+ or 3+ by immunohistochemistry (IHC) were retrospectively identified and treated with T-DXd.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was T-DXd administered and for how long?",{"text":117,"@type":113},"T-DXd was given intravenously at 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and responses were reported in the cohort?",{"text":121,"@type":113},"Among 10 recurrent/metastatic patients, median progression-free survival was 5.4 months. Partial response occurred in 5 patients, stable disease at 12 weeks in 1 patient, and disease progression at initial assessment in 4 patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337119,1790196603,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Andrikopoulou et al. BMC Cancer (2024) 24:1503 [https://doi.org/10.1186/s12885-024-13226-1](https://doi.org/10.1186/s12885-024-13226-1)  \nBMC Cancer  \n RESEARCH Open Access  \nReal-world evidence of Trastuzumab  \nDeruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies  \nAngeliki Andrikopoulou1*, Flora Zagouri1, Kallirroi Goula3, Dimitrios Haidopoulos2, Nikolaos Thomakos2, Anna Svarna1, Meletios-Athanasios Dimopoulos 1 and Michalis Liontos 1  \nAbstract  \nHuman epidermal growth factor receptor 2 (HER2) overexpression emerges as an attractive therapeutic target in gynecological malignancies. Recently, Trastuzumab-Deruxtecan (T-DXd) has shown substantial efficacy in HER2 overexpressing carcinomas, most prominently in ovarian, endometrial and cervical patients. We have examined the efficacy ofT-DXd in patients with metastatic endometrial, ovarian and cervical malignancies that were treated in the Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens.  \nMethods  \nPatients with gynecological malignancies with HER2 expression 2 + /3 + as assessed by immunohistochemistry (IHC) that were treated with T-DXd were retrospectively identified. Patients received T-DXd intravenously at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity.  \nResults  \nIn total, 10 patients treated with T-DXd for recurrent/metastatic disease were identified. Regarding histology, there were 5 patients with uterine neoplasms (serous carcinoma (n= 3), uterine carcinosarcoma (n= 1), uterine leiomyosarcoma (n= 1)), 1 patient with squamous cervical carcinoma and 4 patients with ovarian cancer (ovarian carcinosarcoma (n= 2), high-grade serous carcinoma (n= 1) and mucinous ovarian carcinoma (n= 1)) . Median age was 65.4 years (25th-75th percentile, 58 .1–75. 2 years) . 5 patients had HER2 expression 3 + by IHC and 5 patients had HER2 expression 2 + . Median number of previous lines of therapy was 4 (range 2–6), 2 patients with uterine serous carcinoma were pretreated with trastuzumab and 4 patients had already received immunotherapy. In the entire cohort median progression-free survival (PFS) was 5.4 months (95%CI 0 .8–9. 8 months) . Regarding responses, 5 patients had partial response (including 2 patients that were pretreated with trastuzumab), 1 patient had stable disease at 12 weeks and 4 patients had disease progression at initial assessment. All patients but one that derived clinical benefit had HER2  \n3 + expression.  \nDiscussion  \nIn the real-world setting, T-DXd showed activity in a cohort of heavily pre-treated patients with HER2-expressing gynecological malignancies.  \nKeywords Gynecologic cancer, HER2, T-DXd, DS-8201, Endometrial cancer, Ovarian cancer, Trastuzumab deruxtecan  \n*Correspondence:  \nAngeliki Andrikopoulou  \n[aggelikiandrikop@gmail.com](aggelikiandrikop@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creative","cbCaiqYxD4oYlKtj","https://ap.wps.com/l/cbCaiqYxD4oYlKtj","pdf",1175066,"English","# Abstract\n# Methods\n# Results\n# Discussion\n# Introduction","[{\"question\":\"Which patients were included in the real-world T-DXd efficacy analysis?\",\"answer\":\"Patients with metastatic endometrial, ovarian, and cervical malignancies with HER2 expression 2+ or 3+ by immunohistochemistry (IHC) were retrospectively identified and treated with T-DXd.\"},{\"question\":\"How was T-DXd administered and for how long?\",\"answer\":\"T-DXd was given intravenously at 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity.\"},{\"question\":\"What outcomes and responses were reported in the cohort?\",\"answer\":\"Among 10 recurrent/metastatic patients, median progression-free survival was 5.4 months. Partial response occurred in 5 patients, stable disease at 12 weeks in 1 patient, and disease progression at initial assessment in 4 patients.\"}]","Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies | PDF",1790017763,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50223a4b40900a51761d4701d879c150.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b45de52dd9a625452b04480a7af8a97.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7be1824be09ddf8118c868bf78e15ed0.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc50904d07a07b044dfe63e58b004512.webp",980,1301]